Reporter brief
Pilot RCT of rapamycin with cardiac rehabilitation in older CAD patients shows design only, no results reported
What happened
This is a two-phase study protocol: phase 1 is a dose-escalation pilot in 18 older adults (≥60 years) with coronary artery disease undergoing cardiac rehabilitation, receiving oral rapamycin at 0.5, 1, or 2mg daily with measurement of frailty, quality of life, and senescent biomarkers; phase 2 is a planned RCT comparing exercise alone versus exercise plus low-dose rapamycin. No results are reported here—this is a protocol describing the planned intervention and endpoints.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Patients aged 60 years or older with coronary artery disease undergoing percutaneous coronary intervention (PCI), coronary artery bypass surgery (CABG), or eligible to participate in cardiac rehabilitation
- Design
- Rct
- Sample
- —
- Journal
- Mayo Clinic
- Published
- Dec 7, 2016
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.